GPT and metabolic dysfunction-associated steatotic liver disease: However, no significant difference between two ZM-treated groups and placebo groups regarding ALT, TNF-α, grade of fatty liver in ultrasonography, lipid profiles, and high sensitive C-reactive protein (hs-CRP), while it could improve insulin resistance in patients with NAFLD.